Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510728 | PMC |
| http://dx.doi.org/10.3201/eid2610.201816 | DOI Listing |
Publication Analysis
Top Keywords
covid-19 patient
8
patient sarcoidosis
8
sarcoidosis receiving
8
receiving long-term
8
long-term hydroxychloroquine
8
hydroxychloroquine treatment
8
covid-19
5
treatment france
4
france 2020
4
2020 vitro
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!